[Clinically relevant venous thromboembolism following hip and knee arthroplasty]
Ahn J, Jang EJ, Kim Y, Jung YJ, Yoo JJ, Yoon PW, Lee S
Record ID 32013000527
Korean
Original Title:
슬관절 혹은 고관절 인공관절치환술 환자의 혈전색전증 예방을 위한 항응고제요법 비교연구
Authors' recommendations:
The prevalence of VTE, DVT, and PE within 90 days after hip arthroplasty was 853 (3.8%), 597 (2.7%), and 327 (1.5%), respectively. The prevalence of VTE, DVT, and PE within 90 days after knee arthroplasty was 1,990 (3.8%), 1,699 (3.2%) and 355 (0.7%), respectively.
A previous history of VTE takes a central role in the prevalence of VTE. The prevalence of VTE after hip arthroplasty was 5.7 times higher in patients with a previous history of VTE than in patients with no history of VTE. In terms of the types of arthroplasty, there was a significant difference in revision elective arthroplasty; the prevalence of VTE was 16 times higher in patients with a previous history of VTE who received revision elective arthroplasty. Likewise, the prevalence of VTE after knee arthroplasty was five times higher in patients with a previous history of VTE than in patients with no history of VTE. There was no significant difference among the types of arthroplasty. It is obvious that VTE occurs more commonly in groups with a previous history of VTE in both types of arthroplasty. However, it was not statistically significant in the groups with a previous history of VTE even with the higher prevalence rate. Also, it is not statistically significant in some drug groups either, while the prevalence was higher.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=59
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
South Korea
MeSH Terms
- Arthroplasty, Replacement, Hip
- Arthroplasty, Replacement, Knee
Contact
Organisation Name:
National Evidence-based healthcare Collaborating Agency
Contact Address:
National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.
Contact Name:
int@neca.re.kr
Contact Email:
int@neca.re.kr
Copyright:
National Evidence-based Healthcare Collaborating Agency (NECA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.